Nevro LLC

NVRO · NYSE

Price unavailable right now.

No price history for this range.

NVRO analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Apr 3, 2025

Bull case

Nevro Corp has demonstrated strong revenue growth in the latter half of the year, supported by a comprehensive guidance that includes trials, replacements, competitive conversions, and new patients for 2024. The ongoing scaling of its Costa Rica manufacturing facility is expected to enhance gross margins over the long term, while improvements in operational efficiency are poised to further strengthen profitability. The company is actively investing in its R&D pipeline and diversifying its portfolio, which, along with strategic changes to its commercial team, positions Nevro favorably for continued growth and enhanced market penetration.

Bear case

Nevro Corp's outlook is negatively impacted by a sequential revenue decline, as Q4 revenue of $96.9 million represented a 7% year-over-year decrease, coupled with a 15.2% drop in U.S. trial procedures on an annual basis. The company has also revised its full-year 2024 revenue guidance downwards, projecting $400-405 million, reflecting a decline of 5-6% year-over-year. Furthermore, anticipated lower gross margins in Q4 2024, combined with decreased sales volumes, are expected to create ongoing margin pressures into 2025.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.